undamentalytics Newsletter
Sign in

TG Therapeutics, Inc. key statistics and ratios

In fiscal 2025, TG Therapeutics, Inc. had return on equity of 102.8%, an operating margin of 20.0%, debt equal to 37.9% of equity and a current ratio of 4.10. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Gross margin—————88.2%90.5%94.0%88.3%83.7%82.4%
Operating margin<−999%<−999%<−999%<−999%<−999%<−999%<−999%8.8%12.7%20.0%17.1%
Net margin<−999%<−999%<−999%<−999%<−999%<−999%<−999%5.4%7.1%72.6%55.2%
Free-cash-flow margin<−999%<−999%<−999%<−999%<−999%<−999%<−999%−13.4%−12.3%−4.1%2.2%
Return on equity————−100.1%−92.0%−151.4%11.6%12.2%102.8%70.5%
Return on assets−142.8%−155.7%−191.7%−140.2%−70.8%−69.3%−78.1%4.8%5.2%54.5%32.7%
Asset turnover0.000.000.000.000.000.010.010.890.730.750.59
Current ratio3.013.342.031.776.995.063.165.926.254.104.27
Debt to equity0.2%0.2%0.3%75.5%5.9%28.6%130.9%65.6%109.9%37.9%123.4%
Interest cover (operating income ÷ interest)—n/mn/mn/mn/mn/mn/m1.6x1.7x4.6x3.6x
Effective tax rate———————3.0%8.6%——
R&D as % of revenue>999%>999%>999%>999%>999%>999%>999%32.6%28.7%26.0%28.2%
SG&A as % of revenue———>999%>999%>999%>999%52.5%46.9%37.7%37.1%
Capital spending as % of revenue226.3%1.3%59.2%86.2%234.9%6.0%0.5%0.0%0.0%0.0%0.1%
Free cash flow ÷ net income———————−247.9%−173.5%−5.6%3.9%
Dividends and buybacks ÷ free cash flow——————————>999%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 7 checks passed · June 30, 2026
What it owns · $1.6bn
Short-term assets $1.1bnLonger-term assets $494m
What it owes, and who funded it · $1.6bn
Short-term liabilities $268mLonger-term liabilities $767mShareholders' equity $604m
  • Short-term assets cover short-term liabilities $1.1bn of assets due within a year against $268m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.1bn short-term assets against $767m of longer-dated liabilities.
  • More cash than debt $483m of cash against $745m of debt.
  • Debt below 40% of shareholders' equity Debt is 123% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 28% to 123% over five years.
  • A year's operating cash flow covers at least 20% of debt $18m of operating cash flow against $745m of debt.
  • Operating profit covers interest at least five times over Operating income of $136m against $37m of interest.

From TG Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

9 /100

Weak moat

How hard TG Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -81.3% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -4078.3%; its worst year was -131521.1%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 7 years, at a median -6328.4% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 25.7% over five years; stock-based pay has been a median 423.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (14 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: TGTX vs TLXASND vs TGTXIONS vs TGTXRARE vs TGTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from TG Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to TG Therapeutics, Inc.